Objective Response Rate (ORR)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Objective Response Rate (ORR) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT06520345

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progr…

United States520 participantsStarted 2024-07-26

Treatment: 177Lu-TLX591, Enzalutamide

All recent trials (7 shown)

CompletedNot Applicable

NCT05673967

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Primary Objective: 1\. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with r…

United States62 participantsStarted 2023-01-09

Treatment: Non-Interventional

CompletedPhase 1/2

NCT04815720

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recom…

United States49 participantsStarted 2021-08-09

Treatment: pepinemab + pembrolizumab

Objective Response Rate (ORR)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

All recent trials (7 shown)

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

All recent trials (7 shown)

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Epigenetic Biomarker for Osteosarcoma